Source comparison
Tesamorelin vs Other Visceral Fat Interventions: Comparison
Before comparing interventions, context matters: visceral fat responds poorly to generalised weight loss strategies. Subcutaneous fat mobilises first during caloric deficit, and VAT reduction typically lags by weeks or months. Tesamorelin 2mg/day GHRH analogue
This comparison does not assign a generated winner or score.
- Before comparing interventions, context matters: visceral fat responds poorly to generalised weight loss strategies. Subcutaneous fat mobilises first during caloric deficit, and VAT reduction typically lags by weeks or months.
- Tesamorelin 2mg/day
- GHRH analogue → pulsatile GH release → HSL activation in VAT
- 15–20% mean reduction (CT-verified)
- Minimal (2–3%)
- Significant: fasting insulin ↓15–20%, triglycerides ↓15–25mg/dL, liver enzymes ↓10–15%
- Selective VAT targeting with robust clinical evidence; requires daily injection and GH monitoring for safety
- Caloric Restriction (500kcal deficit)
- Energy deficit → generalised lipolysis across all depots
- 8–12% (varies widely by adherence)
- 10–15% reduction
- Moderate: insulin sensitivity improves proportionally to total weight loss
- Non-selective; VAT loss depends on sustaining deficit long enough to mobilise deeper stores
- GLP-1 Agonist (semaglutide)
- Appetite suppression → caloric deficit + modest metabolic effects
- 10–14% (secondary to total body fat loss)
- 12–18% reduction
- Significant: A1C ↓1.0–1.5%, triglycerides ↓20–30mg/dL
- Effective for total fat mass reduction; VAT improvement is proportional, not preferential
- Resistance Training + Protein
- Muscle protein synthesis → increased RMR and GLUT4 translocation
- 5–8% (requires 6+ months)
- Minimal (muscle gain offsets subcutaneous loss visually)
- Moderate: insulin sensitivity improves via non-insulin-dependent glucose uptake
- Slow VAT reduction; primary benefit is muscle preservation and metabolic health, not fat targeting
- Metformin 1500–2000mg/day
- AMPK activation → reduced hepatic glucose output, modest fat oxidation
- 3–6% (minimal in non-diabetic populations)
- 2–4%
- Modest: fasting glucose ↓5–10mg/dL, minimal triglyceride impact
- Weak VAT-specific effect; primary utility is glucose control, not fat reduction